NPPA fixes retail price of 40 Formulations; Details
The formulations mentioned in the list are combination drugs such as Voglibose + Metformin Tablet; Ramipril + Metoprolol Tablet; Atorvastatin + Clopidogrel + Aspirin Capsule and so on to treat various ailments.
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed prices of 40 formulations. These include some popular drug brands like My Vobo 0.3 M, My GainPro SR2, Oldolan, My Prazol, MyTenslo H, MyLosdro H, Ridzogas SR D, Carnitor Plus and others. The formulations mentioned in the list...
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed prices of 40 formulations.
These include some popular drug brands like My Vobo 0.3 M, My GainPro SR2, Oldolan, My Prazol, MyTenslo H, MyLosdro H, Ridzogas SR D, Carnitor Plus and others. The formulations mentioned in the list are combination drugs such as Voglibose + Metformin Tablet; Ramipril + Metoprolol Tablet; Atorvastatin + Clopidogrel + Aspirin Capsule and so on to treat various ailments, and are manufactured by prominent drugmakers including Zydus Healthcare, Akums Labs, Sun Pharma, Mylan, and others.
This came in exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
| Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1. | Voglibose + | Each uncoated bilayered | 1 Tablet | M/s Akums Drugs & | 6.50 |
|
| Metformin Tablet | tablet contains: |
| Pharmaceuticals Ltd./ |
|
|
| (My Vobo 0.3 M) | Voglibose IP 0.3mg, |
| M/s Mylan |
|
|
|
| Metformin Hydrochloride IP |
| Pharmaceuticals Pvt. |
|
|
|
| 500mg, (Sustained Release) |
| Ltd. |
|
| 2. | Voglibose + | Each uncoated bilayered | 1 Tablet | M/s Akums Drugs & | 5.50 |
|
| Metformin Tablet | tablet contains: |
| Pharmaceuticals Ltd./ |
|
|
| (My Vobo 0.2 M) | Voglibose IP 0.2mg, |
| M/s Mylan |
|
|
|
| Metformin Hydrochloride IP |
| Pharmaceuticals Pvt. |
|
|
|
| 500mg, (Sustained Release) |
| Ltd. |
|
| 3. | Glimepiride + | Each uncoated bilayered | 1 Tablet | M/s Akums Drugs & | 7.30 |
|
| Metformin Tablet | tablet contains: |
| Pharmaceuticals Ltd./ |
|
|
| (My GainPro SR2 | Glimepiride IP 2mg, |
| M/s Mylan |
|
|
| Forte) | Metformin Hydrochloride IP |
| Pharmaceuticals Pvt. |
|
|
|
| 1000 mg, (Prolonged |
| Ltd. |
|
|
|
| Release) |
|
|
|
| 4. | Glimepiride + | Each uncoated bilayered | 1 Tablet | M/s Akums Drugs & | 4.80 |
|
| Metformin Tablet | tablet contains: |
| Pharmaceuticals Ltd./ |
|
|
| (My GainPro SR2) | Glimepiride IP 2 mg, |
| M/s Mylan |
|
|
|
| Metformin Hydrochloride IP |
| Pharmaceuticals Pvt. |
|
|
|
| 500 mg, (Prolonged Release) |
| Ltd. |
|
| 5. | Omeprazole + | Each hard Gelatin capsule | 1 Capsule | M/s Akums Drugs & | 5.10 |
|
| Domperidone | contains: |
| Pharmaceuticals Ltd./ |
|
|
| Capsule (Oldolan) | Omeprazole IP(As Gastro- |
| M/s Mylan |
|
|
|
| Resistant Granules) 20mg, |
| Pharmaceuticals Pvt. |
|
|
|
| Domperidone IP 10mg |
| Ltd. |
|
| 6. | Pantoprazole tablet | Each enteric coated tablet | 1 Tablet | M/s Akums Drugs & | 6.18 |
|
| (My Prazol) | contains: |
| Pharmaceuticals Ltd./ |
|
|
|
| Pantoprazole Sodium IP eq. |
| M/s Mylan |
|
|
|
| to Pantoprazole 40mg, |
| Pharmaceuticals Pvt. |
|
|
|
|
|
| Ltd. |
|
| 7. | Glimepiride + | Each uncoated bilayered | 1 Tablet | M/s Akums Drugs & | 7.80 |
|
| Metformin + | tablet contains: |
| Pharmaceuticals Ltd./ |
|
|
| Pioglitazone Tablet | Glimepiride IP 2 mg, |
| M/s Mylan |
|
|
| (MyGainPro P2) | Metformin Hydrochloride IP |
| Pharmaceuticals Pvt. |
|
|
|
| 500 mg, (Sustained Release |
| Ltd. |
|
|
|
| form) |
|
|
|
|
|
| Pioglitazone Hydrochloride |
|
|
|
|
|
| IP eq. to Pioglitazone 15 mg |
|
|
|
| 8. | Glimepiride + | Each uncoated bilayered | 1 Tablet | M/s Akums Drugs & | 5.90 |
|
| Metformin + | tablet contains: |
| Pharmaceuticals Ltd./ |
|
|
| Piaglitazone Tablet | Glimepiride IP 1 mg, |
| M/s Mylan |
|
|
| (MyGainPro P1) | Metformin Hydrochloride IP |
| Pharmaceuticals Pvt. |
|
|
|
| 500 mg, (Sustained Release |
| Ltd. |
|
|
|
| form) |
|
|
|
|
|
| Pioglitazone Hydrochloride |
|
|
|
|
|
| IP eq. to Pioglitazone 15 mg |
|
|
|
| 9. | Pantoprazole + | Each hard gelatin capsule | 1 Capsule | M/s Akums Drugs & | 13.50 |
|
| Levosulpiride capsule | contains: |
| Pharmaceuticals Ltd./ |
|
|
| (MyPrazol L) | Pantoprazole Sodium IP eq. |
| M/s Mylan |
|
|
|
| to Pantoprazole 40mg (as |
| Pharmaceuticals Pvt. |
|
|
|
| gastro-resistant tablet), |
| Ltd. |
|
|
|
| Levosulpiride 75mg (as uncoated sustained release tablet) |
|
|
|
| 10. | Pantoprazole + Domperidone tablet (MyPrazol D) | Each enteric coated tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg, Domperidone IP 10mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 5.65 |
| 11. | Telmisartan + Hydrochlorothiazide Tablet (MyTenslo H) | Each uncoated bilayered Tablet contains: Telmisartan IP 40mg, Hydrochlorothiazide IP 12.5mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 7.90 |
| 12. | Glimepiride + Metformin Tablet (My GainPro SR1 Forte) | Each uncoated bilayered tablet contains: Glimepiride IP 1 mg, Metformin Hydrochloride IP 1000 mg (Prolonged Release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 6.50 |
| 13. | Glimepiride + Metformin Tablet (My GainPro SR1) | Each uncoated bilayered tablet contains: Glimepiride IP 1mg, Metformin Hydrochloride IP 500 mg, (Prolonged Release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 5.60 |
| 14. | Losartan + Hydrochlorothiazide tablet (MyLosdro H) | Each film coated tablet contains: Losartan potassium IP 50 mg Hydrochlorothiazide IP 12.5 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 7.62 |
| 15. | Telmisartan + Amlodipine Tablet (MyTenslo A) | Each uncoated bilayered Tablet contains: Telmisartan IP 40mg, Amlodipine Besilate IP eq. to Amlodipine 5 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 7.90 |
| 16. | Atorvastatin + Ezetimibe tablet | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg Ezetimibe IP 10 mg | 1 Tablet | M/s East African (India) Overseas / M/s Zydus Healthcare Ltd. | 30.32 |
| 17. | Atorvastatin + Ezetimibe tablet | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg Ezetimibe IP 10 mg | 1 Tablet | M/s East African (India) Overseas / M/s Zydus Healthcare Ltd. | 21.01 |
| 18. | Rabeprazole + Domperidone tablet (Ridzogas D) | Each enteric coated tablet contains: Rabeprazole Sodium IP 20 mg, Domperidone Maleate IP eq. to Domperidone 10 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 5.22 |
| 19. | Rabeprazole + Domperidone Capsule (Ridzogas SR D) | Each hard gelatin capsule contains: Rabeprazole Sodium IP 20 mg (as gastro resistant pellets), Domperidone IP 30 mg (as sustained release pellets) | 1 Capsule | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd. | 8.69 |
| 20. | Norethisteone Acetate Tablet | Each film coated controlled release tablet contains: Norethisteone Acetate BP 10 mg |
1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. | 15.08 |
| 21. | Esomeprazole + Domperidone Capsule | Each hard gelatin capsule contains: Esomeprazole Magnesium IP eq. to Esomeprazole IP 40 mg (as enteric coated pellets) Domperidone IP 30 mg (as sustained release pellets) |
1 Capsule | M/s Skymap Pharmaceuticals Pvt. Ltd. | 9.02 |
| 22. | Glimepiride + Voglibose + Metformin Hydrochloride Tablet | Each uncoated bilayered tablet contains: Glimepiride IP 1 mg Voglibose IP 0.2 mg Metformin Hydrochloride IP 500 mg (as Extended Release ) |
1 Tablet | M/s Sun Pharma Laboratories Ltd. | 8.65 |
| 23. | Glimepiride + Voglibose + Metformin Hydrochloride Tablet | Each uncoated bilayered tablet contains: Glimepiride IP 2 mg Voglibose IP 0.2 mg Metformin Hydrochloride IP 500 mg (as Extended Release ) |
1 Tablet | M/s Sun Pharma Laboratories Ltd. | 12.20 |
| 24. | Atorvastatin + Clopidogrel + Aspirin Capsule | Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg (as film coated tablets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg Aspirin IP 75 mg (As Gastro resistant tablets) |
1 Capsule | M/s Micro Labs. Limited | 3.80 |
| 25. | Atorvastatin + Clopidogrel + Aspirin Capsule | Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg (as film coated tablets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg Aspirin IP 75 mg (As Gastro resistant tablets) |
1 Capsule | M/s Micro Labs. Limited | 5.27 |
| 26. | Levocarnitine + Methylcobalamin + Folic acid tablet (Carnitor Plus) | Each film coated tablet contains: L-Carnitine L-Tartrate Eq. to Levocarnitine 500mg Methylcobalamin IP 1500 mcg Folic acid IP 1.5 mg | 1 Tablet | M/s Modi- Mundipharma Pvt. Ltd. / M/s Win- Medicare Pvt. Ltd. | 13.64 |
| 27. | Ramipril + Metoprolol Tablet | Each film coated bilayered tablet contains: Ramipril IP 2.5 mg Metoprolol Succinate IP 23.75 mg equivalent to Metoprolol Tartrate 25 mg (as extended release form) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Ltd. | 11.08 |
| 28. | Ramipril + Metoprolol Tablet | Each film coated bilayered tablet contains: Ramipril IP 2.5 mg Metoprolol Succinate IP 47.50 mg equivalent to Metoprolol Tartrate 50 mg (as extended release form) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Ltd. | 16.91 |
| 29. | Metformin Hydrochloride + Gliclazide Tablet (Glikey-M) | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (in sustained release form) Gliclazide IP 60 mg (in sustained release form) | 1 Tablet | M/s USV Pvt. Ltd. | 9.47 |
| 30. | Metoprolol + Telmisartan + Chlorthalidone Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50 mg eq. to Metoprolol Tartrate IP (as extended release) 50 mg Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg | 1 Tablet | M/s Sun Pharma Laboratories Ltd. | 12.76 |
| 31. | Metoprolol + Telmisartan + Chlorthalidone Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate IP (as extended release) 25 mg Telmisartan IP 40 mg Chlorthalidone IP12.5 mg | 1 Tablet | M/s Sun Pharma Laboratories Ltd. | 10.78 |
| 32. | Ferric Ammonium Citrate + Vitamin B12 + Folic Acid + Zinc Sulphate Monohydrate Syrup | Each 15 ml syrup contains: Ferric Ammonium Citrate IP 160mg Vitamin B12 IP 5mcg Folic Acid IP 1 mg Zinc Sulphate Monohydrate IP 30mg | 1 ML | M/s Zydus Healthcare Ltd. | 0.50 |
| 33. | Docaravimab + Miromavimab Injection 3000IU /5 ml | Each1ml injection contains: Docaravimab (r-DNA Origin) (INH) 300 IU Miromavimab (r-DNA Origin) (INH) 300 IU | Each Pack | M/s Cadila Healthcare Ltd | 26064.00 |
| 34. | Docaravimab and Miromavimab Injection 3000 IU /10 ml | Each1ml injection contains: Docaravimab (r-DNA Origin) (INH) 150 IU Miromavimab (r-DNA Origin) (INH) 150 IU | Each Pack | M/s Cadila Healthcare Ltd | 26064.00 |
| 35. | Docaravimab and Miromavimab Injection 1500 IU /2.5 ml | Each1ml injection contains: Docaravimab (r-DNA Origin) (INH) 300 IU Miromavimab (r-DNA Origin) (INH) 300 IU | Each Pack | M/s Cadila Healthcare Ltd | 13032.00 |
| 36. | Docaravimab and Miromavimab Injection 600 IU / ml | Each1ml injection contains: Docaravimab (r-DNA Origin) (INH) 300 IU Miromavimab (r-DNA Origin) (INH) 300 IU | Each Pack | M/s Cadila Healthcare Ltd | 5212.80 |
| 37. | Alpha Lipoic Acid + Folic Acid + Methylcobalamin + Vitamin D3 + Pyridoxine Tablets | Each film coated tablet contains: Alpha Lipoic Acid USP 100mg Folic Acid IP 1.5mg Methylcobalamin IP 1500mcg Vitamin D3 IP 1000IU Pyridoxine Hydrochloride (Vitamin B6) IP 3mg | 1 Tablet | M/s East African (India) Overseas / M/s Cadila Pharmaceuticals Limited | 13.33 |
| 38. | Calcium Carbonate + Vitamin D3 + Mecobalamin + L- Methylfolate + Pyridoxal -5 Phosphate Tablet | Each film coated tablet contains: Calcium Carbonate IP 1250 mg eq. to elemental calcium 500 mg Vitamin D3 IP 2000 IU Mecobalamin IP (Methylcobalamin) 1500 mcg L-Methylfolate Calcium 1 mg Pyridoxal -5 Phosphate 20 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Pvt. Ltd. / M/s Cadila Pharmaceuticals Ltd. | 17.59 |
| 39. | Atorvastatin Tablet | Each film coated tablet contains: Atorvastatin Calcium IP eq to Atorvastatin 60mg | 1 Tablet | M/s Intas Pharmaceuticals Limited | 25.00 |
| 40. | Atorvastatin Tablet | Each film coated tablet contains: Atorvastatin Calcium IP eq to Atorvastatin 30mg | 1 Tablet | M/s Intas Pharmaceuticals Limited | 13.96 |
(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS, and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
For more details check out the notice below:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd